The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard
- PMID: 38849166
- DOI: 10.1016/j.jtho.2024.03.004
The Surgical Resection Difficulty From Neoadjuvant Chemoimmunotherapy Is Minimal and Neoadjuvant Therapy Should Be the Standard
Conflict of interest statement
Disclosure Dr. Dickhoff reports receiving research grants and consulting fees from AstraZeneca and Bristol Myers Squibb. Dr. Bahce reports receiving research grants and consulting fees from AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim. Dr. Senan reports receiving research grants from AstraZeneca, ViewRay Inc., and Varian Medical Systems; and consulting fees from ViewRay Inc., AstraZeneca, and Merck Sharp & Dohme. The remaining authors declare no conflict of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
